高压氧联合尼莫地平及依达拉奉治疗重型颅脑损伤患者的安全性及有效性研究
发布时间：2018-08-23 13:49
【摘要】：目的探讨高压氧与尼莫地平、依达拉奉联合治疗重型颅脑损伤的效果及安全性。方法回顾性分析78例重型颅脑损伤患者的临床资料,根据治疗方法的不同分为两组,每组39例。对照组接受常规方案,加高压氧治疗;观察组实施高压氧与尼莫地平、依达拉奉联合治疗。对两组患者疗效、格拉斯哥昏迷评分(GCS)及并发症情况进行观察。结果观察组治疗后总有效率为92.31%,与对照组(76.92%)相比,差异存在统计学意义(P0.05);两组患者不同时间GCS显示,入院时及治疗第1天两组GCS无明显变化,治疗第14、28天,两组患者GCS均有不同程度上升,观察组均高于对照组,差异有统计学意义(P0.05);观察组治疗后不良反应发生率12.82%,对照组为10.26%,两组差异无统计学意义(P0.05)。结论重型颅脑损伤采取高压氧与尼莫地平、依达拉奉联合治疗具有较好疗效,能降低致残率及病死率,治疗安全性高,利于患者尽早康复,值得推广。
[Abstract]:Objective to investigate the efficacy and safety of hyperbaric oxygen combined with nimodipine and Edaravone in the treatment of severe craniocerebral injury. Methods the clinical data of 78 patients with severe craniocerebral injury were analyzed retrospectively. The control group was treated with hyperbaric oxygen plus hyperbaric oxygen, and the observation group was treated with Nimodipine and Edaravone. The curative effect, Glasgow coma score (GCS) and complications were observed. Results the total effective rate was 92.31% in the observation group, which was significantly different from that in the control group (76.92%) (P0.05), the GCS of the two groups at different time showed no significant change on admission and on the first day of treatment, and on the 14th day of treatment, there was no significant change in GCS in the two groups. The GCS of the two groups increased in varying degrees, the observation group was higher than the control group, the difference was statistically significant (P0.05); the incidence of adverse reactions after treatment in the observation group was 12.82, and that in the control group was 10.26. There was no significant difference between the two groups (P0.05). Conclusion Hyperbaric oxygen combined with nimodipine and Edaravone is effective in treating severe craniocerebral injury. It can reduce the rate of disability and mortality, and is safe for patients to recover as soon as possible. It is worth popularizing.
【作者单位】： 四川省达州市第二人民医院神经外科;重庆医科大学附属第一医院神经外科;
【基金】：重庆市科委前沿与应用基础研究项目资助(cstc2014jcyjA10009)
【分类号】：R651.15
[Abstract]:Objective to investigate the efficacy and safety of hyperbaric oxygen combined with nimodipine and Edaravone in the treatment of severe craniocerebral injury. Methods the clinical data of 78 patients with severe craniocerebral injury were analyzed retrospectively. The control group was treated with hyperbaric oxygen plus hyperbaric oxygen, and the observation group was treated with Nimodipine and Edaravone. The curative effect, Glasgow coma score (GCS) and complications were observed. Results the total effective rate was 92.31% in the observation group, which was significantly different from that in the control group (76.92%) (P0.05), the GCS of the two groups at different time showed no significant change on admission and on the first day of treatment, and on the 14th day of treatment, there was no significant change in GCS in the two groups. The GCS of the two groups increased in varying degrees, the observation group was higher than the control group, the difference was statistically significant (P0.05); the incidence of adverse reactions after treatment in the observation group was 12.82, and that in the control group was 10.26. There was no significant difference between the two groups (P0.05). Conclusion Hyperbaric oxygen combined with nimodipine and Edaravone is effective in treating severe craniocerebral injury. It can reduce the rate of disability and mortality, and is safe for patients to recover as soon as possible. It is worth popularizing.
【作者单位】： 四川省达州市第二人民医院神经外科;重庆医科大学附属第一医院神经外科;
【基金】：重庆市科委前沿与应用基础研究项目资助(cstc2014jcyjA10009)
【分类号】：R651.15
【相似文献】
相关期刊论文 前10条
1 卞晓星,薛佳荣,陈斌,杨贵平;126例重型颅脑损伤患者血钾分析[J];中华创伤杂志;2000年09期
2 曾祥富,屈全福,胡涛,张晓海,梁青松;78例交通事故所致重型颅脑损伤的救治[J];中国医师杂志;2000年07期
3 朱自钦,张爱芹,张艳红;重型颅脑损伤的观察及监护管理[J];河南实用神经疾病杂志;2000年03期
4 陈垂尖,庞宏谋,陈敏湘;重型颅脑损伤66例救治体会[J];宁夏医学杂志;2000年04期
5 黄艳素;48例重型颅脑损伤病人的观察及护理[J];右江医学;2000年03期
6 张士霞;重型颅脑损伤急救时的护理配合[J];医学文选;2000年S1期
7 陈礼刚,杨立斌,朴永旭;重型颅脑损伤监护与处理的进展[J];成都军区医院学报;2000年03期
8 任红O，
本文编号：2199261
本文链接：https://www.wllwen.com/yixuelunwen/waikelunwen/2199261.html
最近更新
教材专著
